TGL WHAAAAAAAT! Alerts, thoughts, discussion. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Bishop who started this subject	1/10/2002 3:37:45 PM
From: SSP	Read Replies (1) of 150070

CARA - INDIA'S SUN PHARMA US ARM RECEIVES APPROVAL FOR OXAPROZIN TAB NEW DELHI, Jan 10, 2002 (AsiaPulse via COMTEX) -- Caraco Pharmaceutical Laboratories, the US-based arm of Sun Pharmaceuticals Ltd (BSE:SUN), has received US Food and Drug Administration approval to market and manufacture Oxaprozin tablets, a generic version G. D Searle's anti-rheumatoid, 'Daypro'. The total US market for Oxaprozin is estimated at US$168 million. Detroit-based company last month received a letter of approvability for FDA to produce metformin hydrochloride, a generic form of Bristol Myers Squibb's anti-diabetic Glucophage. "Caraco has 5 additional drugs pending FDA approval and expects to receive approvals for the majority of these by year end," Narendra N Borkar, chief executive officer, Caraco said in a statement here. The company received FDA approval to manufacture and market Carbamazepine(chewable), a generic form of Novartis' 'Tegretol', Clonazepam, a generic form of Roche's 'Klonopin' and Flurbiprofen, a generic form of Pharmacias's 'Ansaid' last year, statement added.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next